Raymond James Financial
BRTX icon

Raymond James Financial’s BioRestorative Therapies BRTX Stock Holding History

Raymond James Financial’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,001
Closed -$5K – 5204
2025
Q2 		$5K Buy
+3,001
New +$5.21K ﹤0.01% 6172

Other funds holding BRTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James Financial's BRTX Position: Q3 2025 in Review

Raymond James Financial sold out of BioRestorative Therapies (BRTX) in Q3 2025, closing a stake of 3,001 shares — an estimated $5K sold.

Raymond James Financial first reported a position in BRTX in Q2 2025 and held it in 1 quarter. The position peaked at $5K in Q2 2025. 14 funds tracked by Wall St. Rank hold BRTX as of Q3 2025.

  • Raymond James Financial reported no remaining BioRestorative Therapies position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3,001 BioRestorative Therapies shares in Q3 2025, an estimated $5K.
  • Raymond James Financial first reported a position in BioRestorative Therapies in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's BioRestorative Therapies position peaked at $5K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.